ArticleMaterials today. Bio2026
Bioprinting and assembly of organ building blocks for tissue engineering applications.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Organ-Specific Migration License (OSML) theory: a novel paradigm for spatiotemporal regulation and intervention of cross-organ immune cell migration in tumor immune responses.Cell communication and signaling : CCS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Damage or functional failure of vital organs remains a major clinical challenge, while the availability of donor organs for transplantation is severely limited. As a result, tissue engineering has emerged as a promising strategy for organ replacement; however, conventional top-down tissue engineering, which employs scaffolds to provide three-dimensional growth environments, cannot ensure precise cell positioning, restricting its applicability to complex and heterogeneous tissues. In contrast, bottom-up strategies that assemble spheroids or organoids as modular building blocks offer a more effective route to organ-like constructs. Nevertheless, they suffer from low reproducibility because of spontaneous cell self-assembly. Three-dimensional bioprinting provides a promising solution for the reproducible fabrication of multicellular organ building blocks (OBBs). At the same time, while extrusion-based bioprinting offers high reproducibility, its limited dimensional accuracy has restricted its use for fabricating OBBs that require both precise microarchitectures and reliable assembly. Here, we address this limitation by introducing a strategy in which bioinks are directly bioprinted within three-dimensionally printed molds, enabling the formation of OBBs with well-defined geometries and controlled spatial organization. By combining mold-guided bioprinting with multimaterial preset extrusion, we demonstrated the fabrication of heterogeneous OBBs with microscale architectures while preserving the modularity essential for bottom-up assembly. This approach resolves the conventional trade-off between structural precision and assembly-based scalability, allowing the construction of large tissue constructs with hierarchical vascular networks. Overall, this work presents a 3D bioprinting-based OBB fabrication strategy that integrates precision manufacturing with bottom-up tissue assembly, offering a reproducible and scalable framework for bioartificial organ engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.